NEW YORK – Proteomics firm Correlia Biosystems said on Friday that it has closed a $7 million Series A funding found.
The company said that the round, which was led by Neotribe Ventures and was joined by Cota Capital, the Regents of the University of California, and others, will support the commercial launch of the company's miniaturized ELISA platform.
By miniaturizing ELISA testing, Correlia reduces the time and sample volume required to run these commonly used protein assays.